Literature DB >> 596101

Effect of diphenylhydantoin on patterns of insulin secretion in obese subjects.

B Draznin, D Ayalon, E Hoerer, Z Oberman, A Harell, R Ravid, L Laurian.   

Abstract

The effect of short-term treatment with diphenylhydantoin (DPH) on the insulin secretion patterns during OGTT and on the daily insulin profile was studied in obese patients. DPH treatment for 3 days with a dose of 300 mg/die (100 mg, 3 times daily) significantly decreased the insulin release after glucose ingestion, but did not alter the basal insulin level. No effect on the fasting glucose concentration as well as on the glucose profiles during OGTT was observed after short-term DPH treatment. A smaller decrease of plasma free fatty acid concentration during OGTT performed after DPH administration confirmed the inhibitory effect of the drug on insulin release. Short-term DPH treatment was also shown to decrease markedly the postpradial insulin release in obese patients. No difference was noted between plasma 11-OHCS and serum HGH concentrations during OGTT before and after DPH treatment. The possible therapeutic role of DPH in obesity is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 596101     DOI: 10.1007/bf02624663

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  31 in total

1.  Effect of diphenylhydantoin on the metabolism of metyrapone and release of ACTH in man.

Authors:  A W Meikle; W Jubiz; S Matsukura; C D West; F H Tyler
Journal:  J Clin Endocrinol Metab       Date:  1969-12       Impact factor: 5.958

2.  Uptake and binding of catecholamines. Effect of diphenylhydantoin and a new mechanism of action.

Authors:  M G Hadfield
Journal:  Arch Neurol       Date:  1972-01

3.  Effect of diphenylhydantoin on cortisol kinetics in humans.

Authors:  Y Choi; K Thrasher; E E Werk; L J Sholiton; C Olinger
Journal:  J Pharmacol Exp Ther       Date:  1971-01       Impact factor: 4.030

4.  Inhibition of insulin secretion by diphenylhydantoin in the isolated perfused pancreas.

Authors:  S R Levin; J Booker; D F Smith; G M Grodsky
Journal:  J Clin Endocrinol Metab       Date:  1970-03       Impact factor: 5.958

5.  Plasma insulin and glucose profiles in normal, obese, and diabetic persons.

Authors:  S M Genuth
Journal:  Ann Intern Med       Date:  1973-12       Impact factor: 25.391

6.  Interference in the effect of dexamethasone by diphenylhydantoin.

Authors:  E E Werk; Y Choi; L Sholiton; C Olinger; N Haque
Journal:  N Engl J Med       Date:  1969-07-03       Impact factor: 91.245

7.  Effect of diphenylhydantoin on insulin secretion in man.

Authors:  C Malherbe; K C Burrill; S R Levin; J H Karam; P H Forsham
Journal:  N Engl J Med       Date:  1972-02-17       Impact factor: 91.245

8.  Insulin secretion in obesity.

Authors:  R A Kreisberg; B R Boshell; J DiPlacido; R F Roddam
Journal:  N Engl J Med       Date:  1967-02-09       Impact factor: 91.245

9.  Effects of diphenylhydantoin (dilantin) on adrenal cortical function; a study in nonepileptic human subjects.

Authors:  P J COSTA; G H GLASER; D D BONNY-CASTLE
Journal:  AMA Arch Neurol Psychiatry       Date:  1955-07

10.  The in vitro inhibition of insulin secretion by diphenylhydantoin.

Authors:  J S Kizer; M Vargas-Gordon; K Brendel; R Bressler
Journal:  J Clin Invest       Date:  1970-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.